Section Arrow
Quote
APVO.NASDAQ
- Aptevo Therapeutics Inc
Quotes are at least 15-min delayed:2026/05/17 05:56 EDT
Regular Hours
Last
 4.77
-0.025 (-0.52%)
Day High 
4.805 
Prev. Close
4.795 
1-M High
5.6931 
Volume 
11.67K 
Bid
4.69
Ask
5
Day Low
4.67 
Open
4.67 
1-M Low
4.25 
Market Cap 
5.67M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.97 
20-SMA 4.98 
50-SMA 4.83 
52-W High 258.012 
52-W Low 1.7501 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-87.27/-18.65
Enterprise Value
9.43M
Balance Sheet
Book Value Per Share
14.71
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
HCWBHCW Biologics Inc1.22+0.883+262.02%-- 
ADTXAditxt Inc.0.0632-0.0036-5.39%-- 
RXRXRecursion Pharmaceuticals2.93-0.11-3.62%-- 
GERNGeron Corp1.29-0.11-7.86%-- 
NTLAIntellia Therapeutics13.67+0.58+4.43%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.